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Abstract:	A	spirocyclic,	sp3-atom	rich	oxetane-containing	scaffold	was	synthesised	in	just	two	steps	via	a	
gold	catalysed	propargylic	alcohol	rearrangement.	The	key	gold	cyclisation	can	be	undertaken	on	a	40	g	
scale	allowing	the	preparation	of	419	lead-like	compounds	based	on	the	scaffold	for	the	European	Lead	
Factory.	
1.	Introduction	
Recent	 initiatives	 in	drug	discovery	have	 focussed	on	 the	development	of	 synthetic	methodologies	 to	
low	 molecular	 weight,	 lead-like,	 sp3-atom	 rich	 molecules;	 that	 have	 the	 potential	 for	 diverse	
functionalisation.1–3	 The	 oxetane	motif	 has	 been	 explored	 in	 drug	 discovery	 due	 to	 its	 impact	 on	 the	
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physicochemical	properties	of	biologically	active	molecules.4–6	Originally	identified	as	isosteres	for	gem-
dimethyl	groups	 increasing	steric	bulk	without	 increased	 lipophilicity,5	oxetanes	also	act	as	bioiosteric	
replacements	for	carbonyls	and	morpholines	(Figure	1).4	
	
Figure	1:	Bioisosteric	roles	of	oxetanes	in	medicinal	chemistry.	
In	 particular,	 spirocyclic	 oxetanes	 (Figure	 2)	 represent	 an	 interesting	 alternative	 scaffold	 due	 to	 their	
intrinsic	high	degree	of	three-dimensional	character,	rigidity	and	well	defined	vectors.7–11	
	
Figure	2:	Recent	examples	of	spirocyclic	oxetane	scaffolds.	
Oxetanes	 can	 be	 prepared	 using	 a	 variety	 of	methods	 including	 the	 intramolecular	Williamson	 ether	
synthesis,10,12,13	 the	 Paterno-Buchi	 reaction,14	 intramolecular	 alkylation,15	 or	 by	 gold	 catalysed	
rearrangement	of	propargylic	alcohols.16	In	keeping	with	our	aim	to	prepare	sp3-atom	rich	scaffolds	for	
drug	discovery,	as	part	of	the	European	Lead	Factory	project,10,17–19	we	identified	the	spirocyclic	oxetane	
scaffold	5	for	inclusion	in	the	Joint	European	Compound	Library	(Figure	3).	
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Figure	3:	The	2-carboxyl-3-alkoxy-1-oxa-7-azaspiro[3,5]nonane	ring	system.	
We	 foresaw	 that	 the	 2-carboxyl-1-oxa-7-azaspiro[3,5]nonane	 scaffold	 5	 should	 be	 accessible	 by	 the	
aforementioned	 gold	 catalysed	 rearrangement	 of	 a	 propargylic	 alcohol	 (Figure	 4),	 	 provided	 that	 the	
reaction	 was	 scalable	 and	 compatible	 with	 other	 functional	 groups.	 We	 now	 report	 the	 successful	
realisation	of	these	goals	that	ultimately	led	to	the	synthesis	of	a	library	of	419	compounds	in	lead-like	
chemical	space.	
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Figure	4	Synthesis	of	key	spirocyclic	oxetane	and	functionalisation	via	gold	catalysed	rearrangement.		
2.	Results	and	Discussion	
The	propargylic	alcohol	7	was	prepared	easily	from	Cbz-protected	piperidinone	6	in	73%	yield	(Scheme	
1).	Alcohol	7	was	then	subjected	to	the	gold	catalysed	rearrangement	conditions,	based	on	the	literature	
procedure.16		Following	these	conditions	we	observed	58%	conversion	into	the	desired	product	(Entry	1,	
Table	1),	with	remaining	starting	material.	Increasing	the	catalyst	loading	to	20	mol%	had	little	effect	on	
this	ratio	(Entry	2,	Table	1).	Increasing	the	temperature	to	60	°C	(Entry	3,	Table	1)	increased	the	yield	to	
74%	with	a	significant	reduction	of	remaining	starting	material.	Pleasingly	we	also	found	that	lowering	
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the	loading	of	the	gold	catalyst	in	this	reaction	from	5%	(as	in	the	literature	procedure)	to	2%,	gave	the	
key	scaffold,	oxetan-3-one	8,	in	a	65%	yield	on	a	17	mmol	scale.	On	a	130	mmol	scale	(43	g),	oxetan-3-
one	8	was	isolated	in	76%	yield.	With	the	core	scaffold	8	in	hand,	further	diversification	was	attempted	
(Scheme	2).		
	
Scheme	1	Preparation	of	oxetan-3-one	8.	Reagents	and	conditions:	a)	n-BuLi	(3.0	eq.),	ethyl	propiolate	
(3.4	eq.),	THF,	-70	°C,	2	h,	43	mmol	scale:	73%,	168	mmol	scale,	77%;	b)	iPrAuNTf2	(2.1	mol%),	Tf2NH	(1.2	
eq.),	4-acetylpyridine	N-oxide	(2	eq.),	1,2-DCE,	60	°C,	24	h,	17	mmol	scale:	65%,	130	mmol	scale:	76%.	
Entrya	 Time	/	h	 Temp	/	°C	 iPrAuNTf2	/	mol%	 	SM	7	/	%a	 	Product	8	/%a	
1	 20	 40	 5	 37	 58	
2	 20	 40	 20	 27	 62	
3	 20	 60	 5	 7	 74	
4b	 72	 60	 5	 0	 0	
5c	 24	 60	 2	 0	 65	
	
Table	1	Optimisation	of	gold	cyclisation.	aReactions	were	conducted	on	a	0.15	mmol	scale	with	1.2	eq.	
Tf2NH,	2	eq.	4-acetylpyridine	N-oxide	in	anhydrous	1,2-DCE,	b0.075	mmol	scale,		c17	mmol	scale.	
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Methylation	 at	 C-4	 with	 caesium	 carbonate	 and	 iodomethane	 was	 unsuccessful	 and	 resulted	 in	 the	
cleavage	of	the	strained	oxetan-3-one	ring	to	tricarbonyl	compound	9.	This	was	based	on	observation	of	
a	new	product	formed	with	the	same	mass	as	the	starting	material,20	and	similar	transformations	in	the	
literature.21		Reductive	amination	of	the	ketone	was	attempted	under	a	range	of	conditions,	but	only	the	
opening	of	the	oxetan-3-one	ring	to	amide	10	or	reduction	to	give	alcohol	11	was	observed	(Scheme	2).		
	
Scheme	 2	 Initial	 attempts	 at	 diversification	 of	 1-oxa-7-azaspiro[3,5]nonane	 core	 8.	 	 Reagents	 and	
conditions	a)	MeI,	Cs2CO3,	DMF,	87%	(mass	recovery).	B)	BnNH2,	Na(OAc)3BH,	1,2-DCE,	35%.	
Reduction	of	the	ketone	was	more	successful	and	the	syn	diastereomer	of	alcohol	11	was	obtained	with	
an	excellent	diastereoselectivity	 (>20:1	by	 1H	NMR	spectroscopy)	using	 sodium	 triacetoxyborohydride	
with	 the	addition	of	acetic	acid	 (Scheme	3).	The	major	diastereomer	was	 isolated	by	chromatography	
and	the	syn	stereochemistry	was	assigned	based	on	1H	NMR	coupling	constants.	The	syn	diastereomer	
was	found	to	have	a	3JHH	coupling	constant	of	7.1	Hz,	corresponding	to	the	expected	0°	dihedral	angle.	In	
contrast,	the	minor	diastereomer	was	found	to	have	a	3JHH	coupling	constant	of	5.5	Hz	corresponding	to	
the	expected	60°	dihedral	angle.22	O-Methylation	of	alcohol	11	could	be	achieved	using	iodomethane	in	
the	presence	of	silver	oxide	and	a	72%	yield	of	12	was	obtained	on	a	small	scale	(200	mg).	This	reaction,	
however,	 was	 not	 compatible	 with	 scale	 up	 conditions	 and	 on	 a	 2.7	 g	 scale,	 the	 yield	 dropped	
dramatically	to	just	23%.	For	this	reason,	further	diversification	of	ether	12	was	not	attempted.	 It	was	
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found	that	the	ester	functionality	in	11	could	be	directly	converted	into	an	amide	by	treatment	with	an	
amine	 and	 DABAL-Me3	 (Scheme	 4).23	 In	 this	 way,	 benzyl	 amide	 13	 and	 isopropyl	 amide	 14	 were	
prepared	 in	 71%	 and	 69%	 yields	 respectively.	 Deprotection	 of	 the	 Cbz	 protecting	 group	 by	
hydrogenolysis	(H2,	Pd/C)	gave	the	amine	scaffolds	15	and	16	ready	for	library	synthesis.		
	
	
Scheme	 3	 Reduction	 and	methylation	 of	 oxetan-3-one	8.	Reagents	 and	 conditions:	 a)	 Na(OAc)3BH	 (2	
eq.),	AcOH	(1.7	eq.),	1,2-DCE,	rt,	18	h,	77%.	b)	Ag2O	(5	eq.),	MeI	(150	eq.),	45	°C,	48	h,	200	mg	scale:	72%	
2.7	g	scale:	23%.	
	
Scheme	4	Functionalising	oxetan-3-ol	11.	Reagents	and	conditions	a)	1.	DABAL-Me3	(1.5	eq.),	RNH2	(1.5	
eq.),	THF,	40	°C,	1	h.	2.	11,	THF,	65	°C,	18	h.	b)	H2,	Pd/C	(10	wt%),	CF3CH2OH,	rt,	15	h.			
2.1	Library	synthesis	
The	synthetic	tractability	of	the	amine	cores	15	and	16	in	library	synthesis	was	tested	on	a	small	scale	at	
Sygnature	Discovery	(Nottingham,	UK)	using	high-throughput	methods.		A	small	library	of	13	compounds	
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was	prepared	by	HATU	mediated	amide	coupling	to	give	amides	17a-c	and	18a-b,	reductive	amination	
to	give	tertiary	amines	17d-f	and	18c-d,	and	reaction	with	sulfonyl	chlorides	to	give	sulfonamides	17g-h	
and	18e	(Scheme	5).		
	
Scheme	 5	 Library	 compounds	 synthesised	 by	 high-throughput	 methods.	 Reagents	 and	 conditions:	 a)	
carboxylic	 acid,	 i-Pr2NEt,	HATU,	DMF,	 18	 h,	 rt.;	 b)	 aldehyde,	 AcOH,	NMe4(OAc)3BH,	DMF,	 18	 h,	 rt.;	 c)	
sulfonyl	chloride,	pyridine,	DMF,	18	h,	rt.			
The	 scaffolds	 prepared	 in	 this	 paper	 were	 developed	 for	 inclusion	 in	 the	 Joint	 European	 Compound	
Library	(JECL)	for	the	European	Lead	Factory,	and	therefore	following	the	small-scale	library	synthesis,	a	
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full	 library	 of	 419	 compounds	 was	 prepared.	 The	 design	 of	 the	 library	 was	 chosen	 to	 consider	 the	
molecular	 properties	 of	 the	 compounds,	 including	 logΡ	 and	 molecular	 weight	 and	 to	 avoid	 any	
potentially	 undesirable	 groups.	 The	 molecular	 weights	 of	 the	 compounds	 within	 the	 library	 were	
between	324	and	445	Da	(Figure	5).	The	molecular	weight	of	the	core	unfunctionalised	scaffold	is	202.	
When	 compared	 to	 two	 commercial	 libraries;	Maybridge	HitCreator	 and	Maybridge	HitFinder	we	 can	
see	that	 the	oxetane	 library	 is	more	densely	clustered	 in	 lead-like	space	compared	to	the	commercial	
libraries	 (Figure	 5).24	 The	 compounds	 have	 a	 high	 fraction	 of	 sp3	 hybridised	 atoms	with	 the	majority	
between	60	and	70%	with	an	average	of	57%;	compared	to	24%	and	31%	for	the	commercial	HitFinder	
and	HitCreator	libraries	respectively	(Figure	6	and	Table	2).	Thus	our	oxetane	library	provides	a	focused	
set	of	compounds	with	more	desirable	“lead-like”	lipophilicity	with	an	fsp3	expected	of	a	candidate	drug	
molecule.		
	
Figure	 5	 Plot	 of	 molecular	 weight	 versus	 cLogΡ	 for	 the	 prepared	 oxetane	 library	 and	 commercial	
libraries.		
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Figure	6	Plot	showing	fraction	of	sp3	hybridised	carbons.	
Library	 Mean	MW	(Da)	 Mean	cLogP	 Mean	Fsp3	
Oxetane	Library	 399.40	 0.89	 57%	
Maybridge	HitFinder	 325.56	 3.30	 23%	
Maybridge	HitCreator	 340.17	 2.87	 30%	
Table	3:	Comparison	of	key	molecular	properties	for	the	oxetane	library	and	two	commercial	libraries.	
	
Figure	 7	 Principal	 moment	 of	 inertia	 plot	 of	 virtual	 library	 of	 oxetanes	 generated	 through	 LLAMA.	
Orange	points	represent	compounds	17a-h	and	18a-e.					
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We	utilised	 the	 library	modelling	 tool	 LLAMA	to	generate	a	principle	moment	of	 inertia	plot	of	 shape	
distribution	for	a	virtual	library	of	compounds	(see	ESI	for	full	details),	and	the	synthesised	compounds	
17a-h	 and	 18a-e	 (Figure	 7).25	 The	 virtual	 library	 of	 molecules,	 along	 with	 the	 synthesised	 examples,	
occupy	the	rod-like	area	of	molecular	space;	reflecting	the	overriding	contribution	of	the	core	scaffold	
for	 molecular	 shape	 –	 allowing	 for	 lead	 optimisation	 with	 a	 variety	 of	 decorating	 groups	 without	
significantly	changing	the	overall	molecule	shape.	
3.	Conclusions	
In	conclusion,	we	have	applied	the	gold	catalysed	rearrangement	of	propargylic	alcohols	to	the	synthesis	
of	functionalized	spirocyclic	oxetane-piperidines	for	drug	discovery.	The	key	gold	rearrangement	can	be	
undertaken	 on	 a	 decagram	 scale	 to	 generate	 the	 oxetan-3-one	 intermediate	 with	 three	 points	 of	
functionalisation.	 The	 scaffold	 can	 be	 further	 elaborated	 to	 prepare	 compound	 libraries	 that	 are	 of	
importance	 to	medicinal	 chemistry	due	 to	 their	 rod-like	 structure.	 This	methodology	has	enabled	 the	
synthesis	of	419	novel	 chemical	entities	with	attractive	physicochemical	properties,	 that	are	available	
through	the	open	access	JECL	for	lead	generation	to	academic	and	industrial	groups.	
		
4.	Experimental	Section	
For	general	experimental	details,	and	protocols	for	library	synthesis,	see	Electronic	Supplementary	
Information.	
Benzyl	4-(3-ethoxycarbonylprop-1-yn-1-yl)-4-hydroxypiperidine-1-carboxylate,	7	
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A	 solution	 of	 ethyl	 propiolate	 (14.8	 mL,	 145.9	 mmol)	 in	 THF	 (120	 mL)	 was	 cooled	 to	 -70	 °C	 in	 an	
acetone/dry	 ice	 bath.	 To	 this	 was	 added	 n-butyllithium	 (2.25	 M	 in	 hexanes,	 57	 mL,	 128.2	 mmol),	
dropwise	over	1	h	and	the	solution	was	stirred	at	-70	°C	for	15	min.	After	this	time,	a	solution	of	1-Cbz-4-
piperidone	6	(10.0	g,	42.9	mmol)	in	THF	(120	mL)	was	added	dropwise	over	an	hour,	ensuring	that	the	
temperature	 did	 not	 rise	 above	 -70	 °C.	 The	 resultant	 solution	was	 stirred	 at	 -70	 °C	 for	 2	 h	 until	 the	
disappearance	of	the	starting	material	was	observed	by	TLC	(50%	ethyl	acetate	in	light	petroleum).	The	
reaction	was	quenched	at	 -70	 °C	by	 the	dropwise	addition	of	a	aqueous	ammonium	chloride	solution	
(saturated,	100	mL)	over	20	min.	The	reaction	mixture	was	warmed	to	room	temperature	extracted	with	
ethyl	acetate	(4	×	100	mL).	The	combined	organic	phases	were	washed	with	brine	(2	×	100	mL),	dried	
(MgSO4)	 and	 the	 solvent	 removed	 in	 vacuo	 to	 give	 a	 brown	 oil	 (21.2	 g).	 Purification	 by	 column	
chromatography	(40%	ethyl	acetate	in	light	petroleum)	gave	the	title	compound	7	as	a	yellow	crystalline	
solid	(10.42	g,	73%):	Rf	0.47	(40%	ethyl	acetate	in	light	petroleum,	weakly	UV	active,	KMnO4	active);	mp	
92-94	 °C;	HRMS	m/z	 (ESI+)	 calcd.	 for	C18H22NO5	 [M+H]+	 requires	332.1492,	 found	332.1498,	 calcd.	 for	
C18H21NNaO5	 [M+Na]+	 requires	 354.1312,	 found	 354.1319;	 νmax	 (ATR)/cm-1	 3388,	 2227,	 1707,	 1673,	
1496,	1472,	1447,	1308,	1161,	1076,	1032,	812,	751;	 1H	NMR	 (400	MHz;	CDCl3)	δ	7.39	–	7.32	 (5H,	m,	
ArH),	5.13	(2H,	s,	CH2Ph),	4.24	(2H,	q,	J	7.2,	OCH2),	3.80	–	3.77	(2H,	m,	CHaHb-2,	CHaHb-6),	3.48	–	3.42	
(2H,	m,	CHaHb-2,	CHaHb-6),	2.33	(1H,	br	s,	OH),	2.02	–	1.91	(2H,	m,	CHaHb-3,	CHaHb-5),	1.85	–	1.73	(2H,	m,	
CHaHb-3,	CHaHb-5),	1.31	(3H,	t,	J	7.2,	CH2CH3);	13C	NMR	 (100	MHz;	CDCl3)	δ	155.2,	153.4,	136.7,	128.7,	
128.2,	128.0,	88.4,	76.8,	67.5,	66.4,	62.5,	40.5,	38.1,	14.1.		
	
7-Benzyl	2-ethyl	3-oxo-1-oxa-7-azaspiro[3.5]nonane-2,7-dicarboxylate,	8	
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A	solution	of	alkyne	7	(5.63	g,	17.0	mmol)	in	dry	dichloroethane	(68	mL)	was	prepared	under	nitrogen.	
To	 this	 was	 added	 sequentially,	 4-acetylpyridine	 N-oxide	 (4.66	 g,	 34.0	 mmol),	 a	 solution	 of	
trifluoromethanesulfonimide	(5.74	g,	20.4	mmol)	in	dry	dichloroethane	(100	mL)	and	iPrAuNTf2	(0.368	g,	
0.43	mmol).	The	solution	was	then	heated	to	60	°C	and	stirred	at	this	temperature	for	24	h.	After	this	
time,	the	solvent	was	removed	 in	vacuo.	Purification	by	column	chromatography	(40%	ethyl	acetate	in	
light	petroleum)	to	give	the	title	compound	8	as	a	yellow	oil	(3.83	g,	65%):	Rf	0.65	(50%	ethyl	acetate	in	
light	petroleum,	UV	 inactive,	weakly	KMnO4	active);	HRMS	m/z	 (ESI+)	 calcd.	 for	C18H21NNaO6	 [M+Na]+	
requires	370.1261,	found	370.1259;	νmax	(ATR)/cm-1	1823,	1747,	1695,	1429,	1237,	1198,	1003,	907,	727;	
1H	NMR	(400	MHz,	CDCl3)	δ	7.43	–	7.27	(5H,	m,	ArH),	5.72	(1H,	s,	CH),	5.13	(2H,	s,	CH2Ph),	4.37	–	4.20	
(2H,	m,	CH2),	3.76	–	3.56	(4H,	m,	CH2),	2.15	–	1.88	(4H,	m,	CH2),	1.31	(3H,	t,	J	7.1,	CH2CH3);	13C	NMR	(100	
MHz;	CDCl3)	δ	196.4,	165.0,	155.2,	136.6,	128.7,	128.3,	128.1,	108.0,	93.7,	67.6,	62.6,	40.1	 (2C),	31.9,	
31.5,	14.3.	
	
Benzyl	4-(benzylcarbamoyl)-4-(2-ethoxy-2-oxoethoxy)piperidine-1-carboxylate,	10	
	
A	 solution	 of	 the	 ketone	 8	 (52	mg,	 0.15	mmol)	 in	 dry	 dichloroethane	 (3.3	 mL)	 was	 prepared	 under	
nitrogen.	To	this	was	added	benzylamine	(24	mg,	25	μL,	0.22	mmol)	followed	by	glacial	acetic	acid	(20	
μL,	0.35	mmol)	and	the	reaction	mixture	was	stirred	at	room	temperature	for	2	h.	After	this	time	sodium	
triacetoxyborohydride	 (64	 mg,	 0.30	 mmol)	 was	 added.	 The	 suspension	 was	 then	 stirred	 at	 room	
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temperature	 for	an	additional	18	h	until	 the	disappearance	of	 the	starting	material	was	confirmed	by	
TLC	(50%	ethyl	acetate	in	light	petroleum).	The	reaction	was	quenched	by	the	addition	of	water	(5	mL)	
and	stirred	for	1	h.	The	reaction	was	extracted	with	dichloromethane	(3	×	5	mL)	and	the	organic	phases	
were	 combined,	 dried	 (MgSO4)	 and	 the	 solvent	 removed	 in	 vacuo.	 Purification	 by	 column	
chromatography	(50%	ethyl	acetate	in	light	petroleum	to	100%	ethyl	acetate)	gave	the	title	compound	
10	as	 a	 colourless	 oil	 (24	mg,	 35%):	Rf	0.70	 (50%	ethyl	 acetate	 in	 light	 petroleum,	weakly	UV	 active,	
KMnO4	active);	HRMS	m/z	(ESI+)	calcd.	for	C24H31N2O5	[M+H]+	requires	427.2227,	found	427.2230;	νmax	
(ATR)/cm-1	1722,	1672,	1640,	1537,	1450,	1242,	1220,	1000;	1H	NMR	 (500	MHz,	CDCl3)	δ	7.59	(1H,	d,	J	
5.9,	NH),	7.30	–	7.15	(10H,	m,	ArH),	5.05	(2H,	s,	OCH2Ph),	4.22	(2H,	d,	J	6.0,	NCH2Ph),	4.03	–	3.87	(6H,	m,	
OCH2CO2Et,	OCH2CH3,	CH2),	3.15	–	2.97	(2H,	m,	CH2),	2.11	–	1.96	(2H,	m,	CH2),	1.78	–	1.62	(2H,	m,	CH2),	
1.12	(3H,	t,	J	7.6,	CH2CH3);	13C	NMR	(125	MHz;	CDCl3)	δ	173.0,	170.2,	155.2,	138.3,	136.7,	128.7,	128.5,	
128.0,	127.9,	127.8,	127.5,	80.2,	67.2,	62.7,	61.6,	43.3,	39.7,	31.7,	14.0.	
	
7-Benzyl	2-ethyl	(2R*,3R*)-3-hydroxy-1-oxa-7-azaspiro[3.5]nonane-2,7-dicarboxylate,	11	
	
A	 solution	 of	 the	 ketone	 8	 (3.51	 g,	 10.1	mmol)	 in	 dry	 dichloroethane	 (222	mL)	 was	 prepared	 under	
nitrogen.	To	this	was	added	sodium	triacetoxyborohydride	(4.29	g,	20.2	mmol)	immediately	followed	by	
glacial	acetic	acid	(0.98	mL,	17.2	mmol)	and	the	suspension	was	stirred	at	room	temperature	for	17	h.	
After	this	time,	additional	sodium	triacetoxyborohydride	(2.14	g,	10.1	mmol)	and	glacial	acetic	acid	(0.5	
mL,	8.1	mmol)	were	added.	The	suspension	was	then	stirred	at	room	temperature	for	an	additional	18	h	
until	 the	 disappearance	 of	 the	 starting	 material	 was	 confirmed	 by	 TLC	 (50%	 ethyl	 acetate	 in	 light	
petroleum).	The	reaction	was	quenched	by	the	addition	of	water	(100	mL)	and	stirred	for	15	min.	The	
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reaction	 was	 extracted	 with	 dichloromethane	 (3	 ×	 100	mL)	 and	 the	 organic	 phases	 were	 combined,	
dried	(MgSO4)	and	the	solvent	removed	in	vacuo	to	give	a	pale	yellow	oil	(3.67	g).	Analysis	of	the	crude	
reaction	mixture	by	1H	NMR	spectroscopy	showed	a	20:1	ratio	of	diastereomers	(syn:anti).	Purification	
by	column	chromatography	(50%	ethyl	acetate	in	light	petroleum)	gave	the	major	diastereomer	11	as	a	
white	oily	solid	(2.70	g,	77%):	Rf	0.21	(50%	ethyl	acetate	in	light	petroleum,	UV	inactive,	KMnO4	active);	
HRMS	m/z	(ESI+)	calcd.	for	C18H24NO6	[M+H]+	requires	350.1598,	found	350.1599,	calcd.	for	C18H23NNaO6	
[M+Na]+	 requires	 372.1418,	 found	 372.1415;	νmax	 (ATR)/cm-1	 3384,	 1721,	 1702,	 1422,	 1222,	 1057;	 1H	
NMR	(400	MHz,	CDCl3)	δ	7.38	-	7.29	(5H,	m,	ArH),	5.12	(2H,	s,	CH2Ph),	5.08	(1H,	d,	J	7.1,	CH),	4.58	(1H,	d,	
J	7.1,	CH),	4.35	-	4.23	(2H,	m,	CH2),	3.73	–	3.62	(2H,	m,	CH2),	3.47	(2H,	tdd,	J	13.2,	9.2,	3.7,	CH2),	3.02	(1H,	
br	s,	OH),	2.10	–	1.72	(4H,	m,	CH2),	1.31	(3H,	t,	J	7.1,	CH2CH3);	13C	NMR	(100	MHz,	CDCl3)	δ	170.5,	155.4,	
136.8,	128.6,	128.2,	128.0,	89.0,	78.8,	72.2,	67.3,	61.7,	40.1,	40.0,	36.6,	30.8,	14.4.	
	
7-Benzyl	2-ethyl	(2R*,3R*)-3-methoxy-1-oxa-7-azaspiro[3.5]nonane-2,7-dicarboxylate,	12	
	
Silver(II)	 oxide	 (660	mg)	was	 added	 to	 a	 solution	 of	 alcohol	 11	 in	 iodomethane	 (12.2	 g,	 5.3	mL,	 86.0	
mmol).	The	reaction	mixture	was	stirred	at	45	°C	for	48	h.	Following	this	time,	the	reaction	mixture	was	
cooled	to	room	temperature	and	filtered	under	vaccum,	the	filtrate	was	washed	with	dichloromethane	
(3	 ×	 10	mL).	 The	 solvent	 was	 removed	 in	 vacuo.	 Purification	 by	 column	 chromatography	 (50%	 ethyl	
acetate	in	light	petroleum)	to	give	the	title	compound	12	as	a	colourless	oil	(150	mg,	72%).	Rf	0.60	(50%	
ethyl	 acetate	 in	 light	petroleum,	UV	 inactive,	KMnO4	active);	HRMS	m/z	 (ESI+)	 calcd.	 for	C19H25NNaO6	
[M+Na]+	requires	386.1574,	found	386.1575;	νmax	(ATR)/cm-1	2933,	1750,	1693,	1428,	1226,	1192,	1131,	
1038,	697;	1H	NMR	(400	MHz,	CDCl3)	δ	7.38	–	7.29	(5H,	m,	ArH),	5.13	(1H,	d,	J	7.3,	CHOMe),	4.28	(2H,	q,	J	
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7.3,	CH2),	4.13	(1H,	d,	J	7.3,	CH),	3.81	–	3.68	(2H,	m,	CH2),	3.47	–	3.36	(2H,	m,	CH2),	3.36	(3H,	s,	OCH3),	
2.14	–	1.77	(4H,	m,	CH2),	1.31	(3H,	t,	J	7.3,	CH2CH3);	13C	NMR	 (100	MHz;	CDCl3)	δ	170.0,	155.4,	136.9,	
128.6,	128.1,	128.0,	89.0,	81.0,	79.2,	67.3,	61.3,	59.4,	40.1,	40.0,	37.2,	30.9,	14.4.	
	
Benzyl	(2R*,3R*)-2-(benzylcarbamoyl)-3-hydroxy-1-oxa-7-azaspiro[3.5]nonane-7-carboxylate,	13	
	
Benzylamine	(87	µL,	0.80	mmol)	was	added	to	a	suspension	of	DABAL-Me3	 (0.21	g,	0.80	mmol)	 in	dry	
THF	(4.3	mL)	under	nitrogen	in	a	Schlenk	flask.	The	flask	was	sealed	and	the	reaction	mixture	was	stirred	
at	40	°C	for	1	h.	After	this	time,	a	solution	of	the	ester	11	(187	mg,	0.54	mmol)	 in	dry	THF	(2	mL)	was	
added	and	the	reaction	mixture	was	stirred	at	65	°C	for	20	h.	The	disappearance	of	the	starting	material	
was	observed	by	TLC	(100%	ethyl	acetate)	and	the	reaction	mixture	was	cooled	to	room	temperature.	
Aqueous	ammonium	chloride	solution	(saturated,	10	mL)	was	added	and	the	product	was	extracted	with	
ether	 (3	×	10	mL).	 The	 solvent	was	 removed	 in	 vacuo.	 Purification	by	 column	chromatography	 (100%	
ethyl	 acetate)	 to	 give	 the	 title	 compound	 13	 as	 a	 colourless	 oil	 (160	mg,	 71%).	 Rf	 0.41	 (100%	 ethyl	
acetate,	 weakly	 UV	 active,	 KMnO4	 active);	 HRMS	 m/z	 (ESI+)	 calcd.	 for	 C23H27N2O5	 [M+H]+	 requires	
411.1914,	 found	411.1913,	 calcd.	 for	 C23H26N2NaO5	 [M+Na]+	 requires	 433.1734,	 found	433.1731;	νmax	
(ATR)/cm-1	3172,	1682,	1646,	1537,	1451,	1431,	1234,	1223,	1002,	729,	695;	1H	NMR	(400	MHz,	CDCl3)	δ	
7.37	–	7.29	(10H,	m,	ArH),	7.17	(1H,	t,	J	6.0,	NH),	5.11	(2H,	s,	CH2Ph),	4.98	(1H,	d,	J	6.6,	CH),	4.64	(1H,	dd,	
J	15.0,	6.0,	NCHaHbPh),	4.56	(1H,	d,	J	6.6,	CH),	4.44	(1H,	dd,	J	15.0,	6.0,	NCHaHbPh),	4.05	(1H,	br	s,	OH),	
3.60	–	3.43	(4H,	m,	CH2),	1.98	(1H,	dt,	J	12.8,	5.7,	CHaHb),	1.83	(2H,	br	s,	CH2),	1.76	–	1.69	(1H,	m,	CHaHb);	
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13C	NMR	(100	MHz;	CDCl3)	δ	170.5,	155.3,	137.5,	136.8,	129.0,	128.7,	128.2,	128.0,	127.9,	127.6,	88.5,	
79.0,	71.6,	67.4,	43.0,	40.33,	40.26,	36.5,	31.5.		
	
Benzyl	(2R*,3R*)-3-hydroxy-2-(isopropylcarbamoyl)-1-oxa-7-azaspiro[3.5]nonane-7-carboxylate,	14	
	
	
iso-Propylamine	 (74	 µL,	 0.86	 mmol)	 was	 added	 to	 a	 suspension	 of	 DABAL-Me3		
(220	mg,	0.86	mmol)	in	dry	THF	(4.6	mL)	under	nitrogen	in	a	Schlenk	flask.	The	flask	was	sealed	and	the	
reaction	mixture	was	stirred	at	40	°C	for	1	h.	After	this	 time,	a	solution	of	 the	ester	11	 (200	mg,	0.57	
mmol)	 in	 dry	 THF	 (2	 mL)	 was	 added	 and	 the	 reaction	 mixture	 was	 stirred	 at	 65	 °C	 for	 20	 h.	 The	
disappearance	 of	 the	 starting	 material	 was	 observed	 by	 TLC	 (100%	 ethyl	 acetate)	 and	 the	 reaction	
mixture	was	cooled	to	room	temperature.	Aqueous	ammonium	chloride	solution	(saturated,	10	mL)	was	
added	 and	 the	 product	 was	 extracted	 with	 ether	 (3	 ×	 10	 mL).	 The	 solvent	 was	 removed	 in	 vacuo.	
Purification	 by	 column	 chromatography	 (100%	 ethyl	 acetate)	 to	 give	 the	 title	 compound	 14	 as	 a	
colourless	oil	(140	mg,	69%).	Rf	0.28	(100%	ethyl	acetate,	weakly	UV	active,	KMnO4	active);	HRMS	m/z	
(ESI+)	calcd.	for	C19H27N2O5	[M+H]+	requires	363.1914,	found	363.1906,	calcd.	for	C19H26N2NaO5	[M+Na]+	
requires	385.1734,	found	385.1734;	νmax	(ATR)/cm-1	3328,	1652	(2),	1532,	1428,	1223,	998,	729;	1H	NMR	
(400	MHz,	CDCl3)	δ	7.38	–	7.30	(5H,	m,	ArH),	6.69	(1H,	d,	J	8.4,	NH),	5.12	(2H,	s,	CH2Ph),	4.87	(1H,	d,	J	6.4,	
CH),	4.59	–	4.56	(2H,	m,	OH	and	CH),	4.13	(1H,	dsept,	J	8.4,	6.6,	CH),	3.66	–	3.44	(4H,	m,	CH2),	2.03	–	1.77	
(4H,	m,	CH2),	1.21	(3H,	d,	J	6.6,	CH3),	1.17	(3H,	d,	J	6.6,	CH3);	13C	NMR	(100	MHz;	CDCl3)	δ	169.7,	155.3,	
136.8,	128.6,	128.1,	128.0,	88.6,	79.3,	71.4,	67.3,	41.2,	40.4,	40.3,	36.6,	31.5,	23.0,	22.7.		
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(2R*,3R*)-N-Benzyl-3-hydroxy-1-oxa-7-azaspiro[3.5]nonane-2-carboxamide,	15	
	
Palladium	 on	 carbon	 (10%,	 44	 mg)	 was	 added	 to	 a	 solution	 of	 amide	 12	 (440	 mg,	 1.07	 mmol)	 in	
trifluoroethanol	(20	mL).	The	flask	was	evacuated	and	a	balloon	of	hydrogen	introduced.	The	suspension	
was	 then	 stirred	 at	 room	 temperature	 for	 26	 h.	 After	 this	 time,	 the	 disappearance	 of	 the	 starting	
material	 was	 observed	 by	 TLC.	 The	 reaction	 mixture	 was	 filtered	 through	 Celite	 and	 extracted	 with	
dichloromethane	 (3	 ×	 10	mL).	 The	 solvent	was	 removed	 in	 vacuo	 to	 give	 the	 title	 compound	15	as	 a	
white	 crystalline	 solid	 (291	 mg,	 99%):	mp	 69-70	 °C;	 HRMS	m/z	 (ESI+)	 calcd.	 for	 C15H21N2O3	 [M+H]+	
requires	 277.1547,	 found	 277.1544,	 calcd.	 for	 C15H20N2NaO3	 [M+Na]+	 requires	 299.1366,	 found	
299.1362;	νmax	(ATR)/cm-1	3250,	2923,	1652,	1526,	1128,	992,	730,	698;	1H	NMR	(400	MHz,	CDCl3)	δ	7.36	
–	7.28	(5H,	m,	ArH),	7.22	(1H,	t,	J	6.0,	NH),	4.98	(1H,	d,	J	7.0,	CH),	4.62	(1H,	dd,	J	15.0,	6.0,	NCHaHbPh),	
4.57	(1H,	d,	J	7.0,	CH),	4.44	(1H,	dd,	J	15.0,	6.0,	NCHaHbPh),	3.01–	2.79	(6H,	m,	OH,	NH	and	2	×	CH2),	2.09	
–	2.03	(1H,	m,	CH2),	1.94	–	1.81	(2H,	m,	CH2),	1.75	–	1.68	(1H,	m,	CH2);	13C	NMR	(100	MHz;	CDCl3)	170.6,	
137.7,	128.9,	127.7,	127.6,	88.8,	79.2,	71.9,	43.0,	42.7,	42.5,	37.5,	32.3.	
	
2R*,3R*)-3-Hydroxy-N-isopropyl-1-oxa-7-azaspiro[3.5]nonane-2-carboxamide,	16	
	
18	
	
Palladium	 on	 carbon	 (10%,	 58	 mg)	 was	 added	 to	 a	 solution	 of	 amide	 13	 (580	 mg,	 1.60	 mmol)	 in	
trifluoroethanol	(20	mL).	The	flask	was	evacuated	and	a	balloon	of	hydrogen	introduced.	The	suspension	
was	 then	 stirred	 at	 room	 temperature	 for	 24	 h.	 After	 this	 time,	 the	 disappearance	 of	 the	 starting	
material	 was	 observed	 by	 TLC.	 The	 reaction	 mixture	 was	 filtered	 through	 Celite	 and	 extracted	 with	
dichloromethane	 (3	 ×	 10	mL).	 The	 solvent	was	 removed	 in	 vacuo	 to	 give	 the	 title	 compound	16	as	 a	
yellow	oily	solid	(358	mg,	98%).	HRMS	m/z	(ESI+)	calcd.	for	C11H21N2O3	[M+H]+	requires	229.1547,	found	
229.1545,	 calcd.	 for	C11H20N2NaO3	 [M+Na]+	 requires	251.1366,	 found	251.1365;	νmax	 (ATR)/cm-1	 3290,	
2932,	1656,	1531,	1130,	999;	1H	NMR	(400	MHz,	CDCl3)	δ	6.71	(1H,	d,	J	8.4,	NH),	4.86	(1H,	d,	J	6.9,	CH),	
4.55	(1H,	d,	J	6.9,	CH),	4.14	(1H,	dsept,	J	8.4,	6.5,	CH),	3.23	(2H,	br	s,	OH	and	NH),	3.03	–	2.96	(2H,	m,	
CH2),	2.89	–	2.79	(2H,	m,	CH2),	2.11	–	2.05	(1H,	m,	CH2),	1.94	–	1.70	(3H,	m,	CH2),	1.21	(3H,	d,	J	6.5,	CH3),	
1.17	(3H,	d,	J	6.5,	CH3);	13C	NMR	 (100	MHz;	CDCl3)	169.7,	89.0,	78.9,	71.7,	42.8,	42.6,	41.2,	37.9,	32.6,	
23.0,	22.7.	
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